Biotech Winners And Losers From Congress’ Latest Funding Bill

Biotech Winners And Losers From Congress’ Latest Funding Bill

Research  these Stocks on Kapitall’s Playground Now

research now

by: Wayne Duggan, Benzinga Staff Writer


Congress introduced the Consolidated Appropriations Act of 2018 on Wednesday, and the bill contains fewer health care provisions than many traders expected.

Still, Height Capital Markets analyst Andrea Harris said on Thursday there are several pharmaceuticals and managed care winners and losers from the new bill.



Among the biggest winners is Omeros Corporation OMER 38.4%.

“Title XIII, which begins on page 2028 of the Consolidated Appropriations Act, is a narrowly designed provision that extends by two years the pass-through status period for qualifying drugs, including OMER's Omidria,” Harris said.

Novartis AG (ADR) NVS 0.79% and Pfizer Inc. PFE 0.94% will continue to benefit from the status quo, but the same can't be said for a couple of other big names.



Amgen, Inc. AMGN 1.91% and Johnson & Johnson JNJ 1.7%investors are likely disappointed the new bill doesn’t include provisions both companies had been pushing for.

“The Consolidated Appropriations Act does not include a separate pass-through-related provision advocated by Amgen and Johnson & Johnson (JNJ) that would have reversed a reimbursement disadvantage that resulted from the 340B payment cuts in the 2018 outpatient prospective payment system (OPPS) rule,” Harris said.

“This policy, which would have applied 340B reimbursement cuts to drugs with pass-through status (they are currently exempt from the cuts) originally surfaced in the House-passed spending bill in February (the Senate version, which became law, did not include the change)."

Congress didn't scale back the required drug discounts sold in the Medicare Part D coverage gap, meaning manufacturers are still on the hook for providing 70 percent discounts starting in 2019.


© 2018 Benzinga does not provide investment advice. All rights reserved.


One response to “Biotech Winners And Losers From Congress’ Latest Funding Bill”

  1. Susan Luna says:

    Miracle Bust is an innovative solution of all natural herbs which invigorates the growth of mammary glands and ultimately leads to natural breast enlargement.

Leave a Reply

Your email address will not be published. Required fields are marked *

  • See Most Recent Articles